Back to search results

Observational Study of Follicular Lymphoma Progression

This observational study aims to better understand follicular lymphoma (a type of cancer affecting lymph nodes) and how it changes over time. Researchers want to collect samples from people with follicular lymphoma to learn more about the disease's biology and how it responds to treatment. This information can help design future treatments. You may be able to join if you are an adult (18 years or older) with follicular lymphoma that has been confirmed by a lab test, and you have not yet started any treatment. The study will look at characteristics of your treatment and molecular biology (like pathology and changes in tissue). It will also measure the time until you start your first systemic treatment (treatment that affects your whole body) over a two-year period. The study is currently unclear about its recruitment status.

Study design
This is an observational study planning to enroll 200 participants. It is not testing a specific intervention or drug.
What's involved
You will have a medical history taken, a physical exam, and answer questions about your daily functioning. You will also provide blood and urine samples.
Compensation
Not stated in the trial record.
Follow-up
The study will measure the time to initiation of first-line systemic treatment for up to 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03190928

Clonal Evolution in Follicular Lymphoma

Recruiting
Not specifiedAges 18+Observational
National Cancer Institute (NCI)
~200 participants
Updated 2026-08-26 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Characteristics of treatment received (e.g., type, response, etc.) and molecular biology (e.g., pathology, histologic transformation) will be described
Measured over ongoing
+1 more outcome measured

Conditions

Follicular Lymphoma

Explore related trials

Follicular Lymphoma

Where it's being run

1 sites across 1 states
Maryland1

Study leadership

  • Rahul Lakhotia, M.D. · PRINCIPAL_INVESTIGATOR · National Cancer Institute (NCI)

Who to contact

NCI Medical Oncology Referral Office
[email protected]
(240) 760-6050
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histologically or cytologically confirmed follicular lymphoma (FL), grades 1-2, or 3a confirmed by the Laboratory of Pathology, NCI; patients who meet criteria for immediate initiation of systemic therapy are eligible
Adequate tissue available from original diagnostic biopsy.

Exclusion

Previous history of diffuse large B-cell lymphoma or histologic transformation
Any prior systemic treatment for lymphoma including cytotoxic chemotherapy, biologic therapy, and monoclonal antibody therapy (radiotherapy permitted); patients who have received chemotherapy, biologic therapy, hormonal therapy, or monoclonal antibody for other malignancies are potentially eligible provided that all of the following are true: a) that malignancy was not lymphoma, b) systemic therapy ended at least 3 years prior to the diagnosis of FL, and c) there is no evidence of active malignancy other than FL
Patients who are HIV-positive
Any second malignancy that requires active systemic therapy
Any other (non-lymphoma) life-threatening disease
Patients unable to provide informed consent (surrogates will not be used)
Pregnant women are excluded from enrollment onto this study because the invasive procedures and/or sedation needed to perform them may cause unnecessary harm to the unborn fetus. In the event a woman becomes pregnant while on study, she will not be removed from the study; however, no follow-up invasive clinical or research procedures will be done that include unacceptable to risk to the patient and/or to the unborn fetus.

What this trial measures

  • Characteristics of treatment received (e.g., type, response, etc.) and molecular biology (e.g., pathology, histologic transformation) will be describedongoing

    The types and frequency of each treatment will be reported.

  • Time to initiation of first-line systemic treatment (TTT1), defined as the number of days from study enrollment until the date of initiation of first-line systemic treatment2 years

    Number of days from study enrollment until the date of initiation of first-line systemic treatment will be reported.